Structural Heart Welcomes You to LAAO

April 24-27, 2025
San Diego, CA

This year’s HRS is going to be one to remember! We are proud to present late breaking data and product advancements for the Amplatzer™ Amulet™ Left Atrial Appendage Occluder. We have made it easy to SAVE THE DATE below, by adding it to your calendar with a click.

Calendar

Fri Apr 25

Sat Apr 26

MAT-2502878 v1.0

CLOSURE. ONCE AND FOR ALL.1,2

We strive to create a passionate community of physicians who not only understand why their patients deserve the life-changing benefits of Amulet but also feel a profound sense of belonging to a global community of Amulet implanters.

Amplatzer™ Amulet™ LAA Occluder

Amulet IDE closure at 12 months3

Chart showing Amulet™ IDE closure at 12 months in comparison with the Watchman‡ 2.5

Swiss-Apero Complete Closure At 45 Days By TEE4

Significantly Higher Complete Closure

Two circle graphs showing 86.3% closure for Amulet™ vs. 72.5% for Watchman‡ FLX
Advance your LAAO practice with Amulet
Download the free AFibLife(tm) App

Tools & Resources

Get the Amplatzer™ Portfolio App

Structural Heart Webinars

Stay up to date on the latest LAAO innovations

Resources for Your Patients

Abbott Cardiovascular supports you with all aspects of patient care. Please find resources to use with your patients.

A Patient’s Guide To The Nonsurgical Closure Of The Left Atrial Appendage

Atrial Fibrillation (AFIB) and the Left Atrial Appendage

AMPLATZER™ AMULET™ LEFT ATRIAL APPENDAGE OCCLUDER
Important Safety Information

INDICATION FOR USE

The Amplatzer™ Amulet™ Left Atrial Appendage Occluder is a percutaneous transcatheter device intended to reduce the risk of thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular atrial fibrillation and who are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores, are suitable for short term anticoagulation therapy, and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation, taking into consideration the safety and effectiveness of the device.

CONTRAINDICATIONS

The Amplatzer™ Amulet™ Left Atrial Appendage (LAA) Occluder is contraindicated for patients:

  • With the presence of intracardiac thrombus.
  • With active endocarditis or other infections producing bacteremia.
  • Where placement of the device would interfere with any intracardiac or intravascular structures.

POTENTIAL ADVERSE EVENTS

Potential adverse events associated with the device or implant procedure include, but are not limited to, the following: Air embolism; Airway trauma; Allergic reaction; Anemia; Anesthesia reaction (nausea, vasovagal reaction, confusion/altered mental status or other); Arrhythmia; Atrial septal defect; Bleeding; Cardiac arrest; Cardiac tamponade; Chest pain/discomfort; Congestive heart failure; Death; Device embolization; Device erosion; Device malfunction; Device malposition; Device migration; Device-related thrombus; Fever; Hematuria; Hypertension/hypotension; Infection; Multi-organ failure; Myocardial infarction; Perforation; Pericardial effusion; Pleural effusion; Renal failure/dysfunction; Respiratory failure; Seizure; Significant residual flow; Stroke; Thrombocytopenia; Thromboembolism: peripheral and pulmonary; Thrombus formation; Transient ischemic attack; Valvular regurgitation/insufficiency; Vascular access site injury (hematoma, pseudoaneurysm, arteriovenous fistula, groin pain or other); Vessel trauma/injury.

REFERENCES

  1. Piayda et al., Safety and feasiblity of peri-device leakage closure after LAAO. Eurointervention. 2022.
  2. Data on file at Abbott
  3. Ellis et al., Incidence and Clinical Outcomes of Peri-Device Leak After Transcatheter LAAO. HRS. 2022.
  4. Galea et al. Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISSAPERO Randomized Clinical Trial. Circulation 2022 145:724-738.